| pubmed-article:19661042 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19661042 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19661042 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:19661042 | lifeskim:mentions | umls-concept:C0278488 | lld:lifeskim |
| pubmed-article:19661042 | lifeskim:mentions | umls-concept:C0332174 | lld:lifeskim |
| pubmed-article:19661042 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:19661042 | lifeskim:mentions | umls-concept:C0728747 | lld:lifeskim |
| pubmed-article:19661042 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:19661042 | pubmed:dateCreated | 2009-8-7 | lld:pubmed |
| pubmed-article:19661042 | pubmed:abstractText | The use of trastuzumab in combination with either a taxane or vinorelbine has improved the efficacy of treatment for women with HER2-positive (HER+) breast cancer. We investigated the activity and toxicity of the gemcitabine/trastuzumab combination as first- or second-line treatment in women with HER2+ metastatic breast cancer (MBC). | lld:pubmed |
| pubmed-article:19661042 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19661042 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19661042 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19661042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19661042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19661042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19661042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19661042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19661042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19661042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19661042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19661042 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19661042 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:19661042 | pubmed:issn | 1938-0666 | lld:pubmed |
| pubmed-article:19661042 | pubmed:author | pubmed-author:HainsworthJoh... | lld:pubmed |
| pubmed-article:19661042 | pubmed:author | pubmed-author:GrecoF... | lld:pubmed |
| pubmed-article:19661042 | pubmed:author | pubmed-author:BurrisHoward... | lld:pubmed |
| pubmed-article:19661042 | pubmed:author | pubmed-author:SpigelDavid... | lld:pubmed |
| pubmed-article:19661042 | pubmed:author | pubmed-author:YardleyDenise... | lld:pubmed |
| pubmed-article:19661042 | pubmed:author | pubmed-author:HansonSarahS | lld:pubmed |
| pubmed-article:19661042 | pubmed:author | pubmed-author:BartonJohnJ | lld:pubmed |
| pubmed-article:19661042 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19661042 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:19661042 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19661042 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19661042 | pubmed:pagination | 178-83 | lld:pubmed |
| pubmed-article:19661042 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:19661042 | pubmed:meshHeading | pubmed-meshheading:19661042... | lld:pubmed |
| pubmed-article:19661042 | pubmed:meshHeading | pubmed-meshheading:19661042... | lld:pubmed |
| pubmed-article:19661042 | pubmed:meshHeading | pubmed-meshheading:19661042... | lld:pubmed |
| pubmed-article:19661042 | pubmed:meshHeading | pubmed-meshheading:19661042... | lld:pubmed |
| pubmed-article:19661042 | pubmed:meshHeading | pubmed-meshheading:19661042... | lld:pubmed |
| pubmed-article:19661042 | pubmed:meshHeading | pubmed-meshheading:19661042... | lld:pubmed |
| pubmed-article:19661042 | pubmed:meshHeading | pubmed-meshheading:19661042... | lld:pubmed |
| pubmed-article:19661042 | pubmed:meshHeading | pubmed-meshheading:19661042... | lld:pubmed |
| pubmed-article:19661042 | pubmed:meshHeading | pubmed-meshheading:19661042... | lld:pubmed |
| pubmed-article:19661042 | pubmed:meshHeading | pubmed-meshheading:19661042... | lld:pubmed |
| pubmed-article:19661042 | pubmed:meshHeading | pubmed-meshheading:19661042... | lld:pubmed |
| pubmed-article:19661042 | pubmed:meshHeading | pubmed-meshheading:19661042... | lld:pubmed |
| pubmed-article:19661042 | pubmed:meshHeading | pubmed-meshheading:19661042... | lld:pubmed |
| pubmed-article:19661042 | pubmed:meshHeading | pubmed-meshheading:19661042... | lld:pubmed |
| pubmed-article:19661042 | pubmed:meshHeading | pubmed-meshheading:19661042... | lld:pubmed |
| pubmed-article:19661042 | pubmed:meshHeading | pubmed-meshheading:19661042... | lld:pubmed |
| pubmed-article:19661042 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19661042 | pubmed:articleTitle | Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer. | lld:pubmed |
| pubmed-article:19661042 | pubmed:affiliation | Sarah Cannon Research Institute, Nashville, TN 37203, USA. dyardley@tnonc.com | lld:pubmed |
| pubmed-article:19661042 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19661042 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19661042 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:19661042 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
